Mesenchymal stem cells: current clinical progress in ARDS and COVID-19

Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Kun, Hou, Fei, Huang, Xiuyu, Li, Binbin, Qian, Zhi Rong, Xie, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373844/
https://www.ncbi.nlm.nih.gov/pubmed/32698898
http://dx.doi.org/10.1186/s13287-020-01804-6
_version_ 1783561571097640960
author Xiao, Kun
Hou, Fei
Huang, Xiuyu
Li, Binbin
Qian, Zhi Rong
Xie, Lixin
author_facet Xiao, Kun
Hou, Fei
Huang, Xiuyu
Li, Binbin
Qian, Zhi Rong
Xie, Lixin
author_sort Xiao, Kun
collection PubMed
description Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic.
format Online
Article
Text
id pubmed-7373844
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73738442020-07-22 Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 Xiao, Kun Hou, Fei Huang, Xiuyu Li, Binbin Qian, Zhi Rong Xie, Lixin Stem Cell Res Ther Review Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic. BioMed Central 2020-07-22 /pmc/articles/PMC7373844/ /pubmed/32698898 http://dx.doi.org/10.1186/s13287-020-01804-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Xiao, Kun
Hou, Fei
Huang, Xiuyu
Li, Binbin
Qian, Zhi Rong
Xie, Lixin
Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
title Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
title_full Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
title_fullStr Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
title_full_unstemmed Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
title_short Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
title_sort mesenchymal stem cells: current clinical progress in ards and covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373844/
https://www.ncbi.nlm.nih.gov/pubmed/32698898
http://dx.doi.org/10.1186/s13287-020-01804-6
work_keys_str_mv AT xiaokun mesenchymalstemcellscurrentclinicalprogressinardsandcovid19
AT houfei mesenchymalstemcellscurrentclinicalprogressinardsandcovid19
AT huangxiuyu mesenchymalstemcellscurrentclinicalprogressinardsandcovid19
AT libinbin mesenchymalstemcellscurrentclinicalprogressinardsandcovid19
AT qianzhirong mesenchymalstemcellscurrentclinicalprogressinardsandcovid19
AT xielixin mesenchymalstemcellscurrentclinicalprogressinardsandcovid19

Ejemplares similares